另一发展方面，董事会欣然宣布，于2025年11月19日，公司就针对过敏性结膜炎的盐酸依匹斯汀滴眼液 取得国家药监局的上市批准。 格隆汇11月24日丨兆科眼科-B(06622.HK)宣布，于2025年11月18日，中国国家药监局已批准公司就 PAN-90806滴眼液用于治疗湿性(新生血管性)老年黄斑部病变("wAMD")作出的新药临床试验申请。 盐酸依匹斯汀为用于治疗过敏性结膜炎的依匹斯汀滴眼液，具有抗组胺及稳定肥大细胞的双重作用机 制，是中国过敏性结膜炎(尤其是急性患者)的一线疗法。我们的盐酸依匹斯汀为Elestat的仿制药。 Elestat由艾尔建开发。 据悉，PAN-90806，一种用于治疗wAMD的抗VEGF药物，为一种新型滴眼液配方，属于小分子复合 物，具有良好的物理化学特性，可供外用。PAN-90806如获批准作为维持疗法，将为患者带来极大便利 性及较小侵入性的治疗选择，降低主流抗VEGF疗法中的玻璃体腔内注射频率及其他相关治疗负担，同 时维持视力稳定性。预期使用PAN-90806将大幅减少治疗中断的情况，从而通过提升患者舒适性、接受 性、便捷性及遵医嘱性减缓相关疾病恶化。 ...

Company Overview - Oculis is a Swiss biotechnology company founded in 2017, focusing on the development of dissolving nanoparticle technology for eye treatments [2] - The company was co-founded by Einar Stefánsson and Thorsteinn Loftsson, both of whom have extensive academic and professional backgrounds in ophthalmology and pharmaceutical chemistry [2] - Oculis is headquartered in Switzerland and operates in the United States, China, and Europe [2] Technology and Products - Oculis has developed a proprietary technology called OPTIREACH®, which enhances the delivery of eye drops to the back of the eye, improving treatment for various eye diseases [6] - The lead product, OCS-01, is a preservative-free eye drop formulation combining dexamethasone with OPTIREACH® technology, aimed at treating diabetic macular edema (DME) [6] - OCS-01 is currently in Phase 3 clinical trials, showing effectiveness in improving vision and reducing central macular thickness in patients with DME [6] Market Context - Diabetic macular edema affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [4] - Current treatments for DME are primarily invasive, often requiring frequent injections, which can be burdensome for patients [4] - Oculis's non-invasive approach with OCS-01 offers a more comfortable and convenient treatment option for millions of patients suffering from retinal diseases [6] Additional Pipeline Products - Besides OCS-01, Oculis is developing OCS-02, a topical anti-TNF-α monoclonal antibody fragment for dry eye treatment, currently in Phase 2b clinical studies [7] - OCS-05 is another product aimed at protecting nerve axons in acute optic neuritis and other neuro-ophthalmic diseases, currently undergoing clinical research in Europe [7] Financial and Market Position - Oculis went public on NASDAQ following a SPAC merger with European Biotech Acquisition Corp on March 3, 2023 [7] - The company raised $59 million in an oversubscribed private placement in April 2024 and secured an additional $100 million in February 2025 to accelerate product development [7] - Oculis was recognized in the 2022 TOP100 Swiss Startups list, highlighting its innovative potential and market prospects in the biotechnology sector [9]